

## AMENDMENT

### In the Specification:

Please insert at page 4, line 26, substitute --C-terminal-- for the second recitation of "N-terminal".

At page 34, line 25 and at page 35, line 1, following the recitation of "Example", substitute --2C-- for "3C".

### In the Claims:

1. (Amended) A [peptide-type] compound or variant thereof having lymphocyte immunomodulating activity [including the] , wherein said compound comprises N-terminal acylated and/or C-terminal amidated or esterified forms [thereof] , wherein said compound further comprises from at least 12 [of] up to 60 amino acids wherein said [peptide-type] compound comprises the formula:

$\alpha$ - $\beta$

wherein:

$\alpha$  and  $\beta$  are the same or different and are of the formula:

(a) {R aa<sup>76-77</sup> L} (aa<sup>79-84</sup>)

or

(b) (aa<sup>84-79</sup>) {L aa<sup>77-76</sup> R}

wherein:

aa<sup>76</sup> is E or V;

aa<sup>77</sup> is D, S or N;

aa<sup>79</sup> is R or G;

aa<sup>80</sup> is I or N;

aa<sup>81</sup> is a hydrophobic or small amino acid;

aa<sup>82</sup> is R or L;

aa<sup>83</sup> is G or R;